Skip to main navigation Skip to search Skip to main content

Volume-assured pressure support mode plus pirfenidone as resuscitation therapy in patients with exacerbation of idiopathic pulmonary fibrosis

  • Killen Harold Briones Claudett*
  • , Mónica H.Briones Claudett
  • , Estupiñan Vargas Domenica
  • , Stalin Rodriguez Garcia
  • , Cesar Andrade Cabrera
  • , Jaime Benites Solis
  • , Michelle Grunauer Andrade
  • *Corresponding author for this work
  • Universidad de Guayaquil
  • Centro Fisiológico-Respiratorio Briones-Claudett
  • Ecuadorian Institute of Social Security
  • Omni Hospital
  • School of Medicine

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: Treatment among advanced stage idiopathic pulmonary fibrosis is quite challenging, especially considering that no major evidence has been released about it. This case report demonstrates and discusses the benefit of non-invasive mechanical ventilation in volume-assured pressure support (AVAPS) mode plus pirfenidone based on the relief of a patient’s symptoms in combination with high-resolution computed tomography (HRCT) evidence. Material and methods: An 83-year-old female patient with multiple hospital admissions within a six-month period initially presented with cardiac symptoms which were later attributed to a possible exacerbation of her primary diagnosis, idiopathic pulmonary fibrosis. Conclusion: The addition of non-invasive mechanical ventilation in AVAPS mode plus pirfenidone can improve the survival rates even in patients with current exacerbations of acute respiratory failure due to idiopathic pulmonary fibrosis.

Original languageEnglish
Pages (from-to)147-152
Number of pages6
JournalAdvances in Respiratory Medicine
Volume88
Issue number2
DOIs
StatePublished - 2020

Keywords

  • Idiopathic pulmonary fibrosis
  • Non-invasive ventilator
  • Pirfenidone

Fingerprint

Dive into the research topics of 'Volume-assured pressure support mode plus pirfenidone as resuscitation therapy in patients with exacerbation of idiopathic pulmonary fibrosis'. Together they form a unique fingerprint.

Cite this